Liquidia Corporation (LQDA) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
LQDA Q1 2026: Utrepia Drives 44% Sequential Sales Growth, Anchoring Category Leadership
May 11, 2026
-
Liquidia (LQDA) Q4 2025: Eutrepia Captures 17% Market Share, Outpaces Inhaled Prostacyclin Growth
March 05, 2026
-
Liquidia (LQDA) Q3 2025: Eutropia Captures 75% of Inhaled Prostacyclin Market Growth
November 03, 2025
-
Liquidia (LQDA) Q2 2025: Eutrepia Prescriptions Top 900 in 11 Weeks, Accelerating Prostacyclin Market Disruption
August 12, 2025
-
Liquidia (LQDA) Q1 2025: 48% G&A Surge Signals Full-Scale Launch Readiness for Utrepia
July 07, 2025